Strategy

Four tips for midsized companies when entering new global markets.

LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses strategies to address underrepresentation in clinical trials, particularly in phase III psoriasis trials.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, explores practical steps pharmaceutical executives can take to foster better collaboration within their organizations, as well as with external partners like providers and pharmacies.

Applying the McKinsey 7S Framework to TLL and regional marketing teams.

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

A look at the current landscape and how young companies can set the stage for product launch.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores ways that digital health platforms can assist pharma companies seeking to maintain accessibility and manage cost pressures.

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.

In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.

HEOR requires executive leaders who have both scientific and managerial acumen.

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies strategies pharmaceutical companies can use to combat misinformation on social media.

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, speaks about how distrust and uncertainty surrounding social media is impacting the pharmaceutical industry.